Treatment of XXXX with @entity1154 @entity535 precursors and organic cation transporter assay interpretation.

@entity1 @entity535 @entity935 @entity71 @entity750 @entity1154
BACKGROUND: This paper documents a retrospective pilot study of a novel approach for treating @entity71 ( @entity71 ) with @entity535 precursors of @entity750 and @entity935 in conjunction with urinary @entity1154 assays subjected to organic cation transporter (OCT) functional status determination. The goal of this research was to document the findings and related considerations of a retrospective chart review study designed to identify issues and areas of concern that will define parameters for a prospective controlled study. METHODS: This study included 85 @entity1 , aged 4-18 years, who were treated with a novel @entity535 precursor protocol. Their clinical course during the first 8-10 weeks of treatment was analyzed retrospectively. The study team consisted of PhD clinical psychologists, individuals compiling clinical data from records, and a statistician. The @entity1 had been treated with a predefined protocol for administering @entity535 precursors of @entity750 and @entity935 , along with OCT assay interpretation as indicated. RESULTS: In total, 67% of @entity1 achieved significant improvement with only @entity535 precursors of @entity750 and @entity935 . In @entity1 who achieved no significant relief of symptoms with only @entity535 precursors, OCT assay interpretation was utilized. In this subgroup, 30.3% achieved significant relief following two or three urine assays and dosage changes as recommended by the assay results. The total percentage of @entity1 showing significant improvement was 77%. CONCLUSION: The efficacy of this novel protocol appears superior to some @entity71 prescription drugs, and therefore indicates a need for further studies to verify this observation. The findings of this study justify initiation of further prospective controlled studies in order to evaluate more formally the observed benefits of this novel approach in the treatment of @entity71 .
